By Brian Cohen
According to a recent research study, some of the patients inoculated with Zostavax, the shingles vaccine created by Merck, shed the varicella virus through their saliva and inoculation sites for a month after immunization.
The research, conducted by Dr. Catherine DiGiorgio of the University of Texas – Houston, may have positive and negative implications on the latest recommendation by the Centers for Disease Control and Prevention that all adults over 60 receive the vaccine, according to Fierce Vaccines.
A retrospective study in January showed that Merck’s live accentuated varicella virus halved the risk of developing shingles. Dr. DiGiorgio and other researchers do not yet know if the virus shed after immunization is infectious.